Zeneca Casodex Clinical Trial Excerpts Cited In FDA Warning Letter
Executive Summary
Zeneca's distribution of three leaflets excerpting clinical trial results for the prostate cancer therapy Casodex (bicalutamide) for off-label uses is among promotional activities by the company challenged in a Nov. 24 warning letter.
You may also be interested in...
FDA Response Time For DTC Ad Advisory Comments Has Doubled, Agency Says
FDA has increased from two to four weeks the time it takes to return direct-to-consumer broadcast ads with advisory comments due to the enlarged volume of submissions, Division of Drug Marketing, Advertising & Communications Branch Chief Nancy Ostrove, PhD, reported Sept. 13 at a Food & Drug Law Institute conference on "Marketing and Promotion in the New Millennium."
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011